Antibacterial therapy of community-acquired bacterial meningitis in children is changing worldwide, and 1 currently recommended option includes the use of meropenem as monotherapy. Data presented at a Zeneca-sponsored symposium at the 9th European Congress of Clinical Microbiology and Infectious Diseases [Berlin, Germany; March 1999] confirmed the efficacy and favourable safety profile of meropenem in children with bacterial meningitis.